Longitudinal Molecular Epidemiology and Genomic Surveillance of Carbapenem‐Resistant Klebsiella pneumoniae in the Gut of Healthy Individuals in China
MedComm · 2026-08 · 7 (8)
DOI: 10.1002/mco2.70814 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm, online erschienen am 05.08.2026. Verfasst von Zelin Yan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, School of Medicine Second Affiliated Hospital of Zhejiang University Hangzhou China. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Carbapenem‐resistant Klebsiella pneumoniae (CRKP) was identified by the World Health Organization in 2024 as a key priority bacterium for the development of novel control strategies. While most surveillance studies have focused on clinical isolates, the prevalence and genomic characteristics of CRKP in healthy populations remain poorly understood. Here, we present a nationwide longitudinal descriptive genomic analysis of CRKP isolates from healthy individuals in China in 2016 and from 2019 to 2024. Within this hospital‐based health‐check cohort, CRKP prevalence was higher in southern regions. Descriptive temporal changes in carbapenemase gene composition were observed, with bla NDM variants, especially bla NDM‐5 , more frequently detected in later years and often associated with IncHI2‐IncHI2A plasmids. ST11, primarily represented by capsular types KL47 and KL64, remained the predominant lineage throughout the study period. Gene presence/absence association analysis identified several ST11‐enriched loci related to iron acquisition, capsular polysaccharide synthesis, and secretion‐associated functions, highlighting candidate lineage‐associated features. Comparative genomic analysis with 113 clinical CRKP isolates revealed high genetic similarity (SNP < 100) between some healthy‐carrier and clinical strains, suggesting possible clonal relatedness. These findings indicate that healthy individuals in this hospital‐based cohort can harbor clinically relevant CRKP, supporting surveillance beyond symptomatic infections while emphasizing the descriptive scope of the present study.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory, School of Medicine Second Affiliated Hospital of Zhejiang University Hangzhou China.
- School of Pharmaceutical Sciences Zhengzhou University Zhengzhou China.
- Jiangsu Co-Innovation Center For Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine Yangzhou University Yangzhou China.
- Department of Laboratory Medicine, the First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China.
- Department of Clinical Laboratory, School of Medicine, Tianjin First Central Hospital Nankai University Tianjin China.
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Yan, Z., Li, Y., Sun, Y., Sun, Q., Liu, C., Zhang, Y., Wu, Y., Zhou, H., Qin, S., Chen, G., Li, R., & Zhang, R. (2026). Longitudinal Molecular Epidemiology and Genomic Surveillance of Carbapenem‐Resistant Klebsiella pneumoniae in the Gut of Healthy Individuals in China. MedComm, 7(8). https://doi.org/10.1002/mco2.70814
Vancouver
Yan Z, Li Y, Sun Y, Sun Q, Liu C, Zhang Y, et al. Longitudinal Molecular Epidemiology and Genomic Surveillance of Carbapenem‐Resistant Klebsiella pneumoniae in the Gut of Healthy Individuals in China. MedComm. 2026;7(8). doi:10.1002/mco2.70814
BibTeX
@article{Yan2026,
author = {Yan, Zelin and Li, Yan and Sun, Yi and Sun, Qiaoling and Liu, Congcong and Zhang, Yanyan and Wu, Yuchen and Zhou, Hongwei and Qin, Shangshang and Chen, Gongxiang and Li, Ruichao and Zhang, Rong},
title = {Longitudinal Molecular Epidemiology and Genomic Surveillance of Carbapenem‐Resistant Klebsiella pneumoniae in the Gut of Healthy Individuals in China},
journal = {MedComm},
year = {2026},
volume = {7},
number = {8},
doi = {10.1002/mco2.70814}
}
EUVIMED